Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Mana Aizawa"'
Autor:
Masatoshi Kudo, Kenta Motomura, Yoshiyuki Wada, Yoshitaka Inaba, Yasunari Sakamoto, Masayuki Kurosaki, Yoshiko Umeyama, Yoichi Kamei, Junichiro Yoshimitsu, Yosuke Fujii, Mana Aizawa, Paul B. Robbins, Junji Furuse
Publikováno v:
Liver Cancer, Pp 1-11 (2021)
Introduction: Combining an immune checkpoint inhibitor with a targeted antiangiogenic agent may leverage complementary mechanisms of action for the treatment of advanced/metastatic hepatocellular carcinoma (aHCC). Avelumab is a human anti-PD-L1 IgG1
Externí odkaz:
https://doaj.org/article/b8be2ef681554e6887c3892833ec2d08
Publikováno v:
Biometrical Letters. 58:81-94
Summary In clinical research, collected data are often classified into ordered categories using a set threshold to evaluate efficacy and safety of treatment. Data can be summarized as a shift table, which displays the change in the frequency of subje
Autor:
Takaaki Ono, Masayuki Hino, Itaru Matsumura, Shin Fujisawa, Kenichi Ishizawa, Emiko Sakaida, Naohiro Sekiguchi, Chiho Ono, Mana Aizawa, Yusuke Tanetsugu, Yuichiro Koide, Naoto Takahashi
Publikováno v:
International journal of hematology. 116(6)
Bosutinib has been evaluated for treatment of chronic-phase chronic myeloid leukemia (CP-CML) in several clinical studies, including in Japan. This open-label, single-arm, phase 2 study evaluated the efficacy and safety of bosutinib at a starting dos
Publikováno v:
SUT Journal of Mathematics. 57
Autor:
Takaaki Ono, Yusuke Tanetsugu, Shin Fujisawa, Itaru Matsumura, Yuichiro Koide, Emiko Sakaida, Naohiro Sekiguchi, Mana Aizawa, Naoto Takahashi, Chiho Ono, Masayuki Hino, Kenichi Ishizawa
Publikováno v:
Blood. 138:2557-2557
Introduction : Bosutinib is approved in Japan for patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic phase (CP) chronic myeloid leukemia (CML) and Ph+ CML resistant/intolerant to prior therapy. In the primary report of a pha
Autor:
Takashi Matsumoto, Hideki Tokunaga, Kan Yonemori, Hiroyuki Fujiwara, Shoji Nagao, Noriyuki Katsumata, Harushige Yokota, Keiichi Fujiwara, Hidemichi Watari, Katsutoshi Oda, Tomoko Okubo, Toshiaki Nakamura, Takeshi Hirasawa, Mana Aizawa
Publikováno v:
Annals of Oncology. 30:vi89
Background JAVELIN Ovarian 200 (NCT02580058), a randomized, open-label, phase 3 trial, investigated avelumab (Ave; anti-PD-L1) alone or Ave + pegylated liposomal doxorubicin (PLD) vs PLD alone in patients (pts) with PRROC. In the overall population (
Autor:
Masatoshi Kudo, Yoshiko Umeyama, Masayuki Kurosaki, Junichiro Yoshimitsu, Yoshitaka Inaba, Junji Furuse, Kenta Motomura, Yasunari Sakamoto, Yoichi Kamei, Paul B. Robbins, Mana Aizawa, Yoshiyuki Wada, Yosuke Fujii
Publikováno v:
Journal of Clinical Oncology. 37:4072-4072
4072 Background: Combining an immune checkpoint inhibitor with a targeted antiangiogenic agent may leverage complementary mechanisms of action for treatment of advanced/metastatic (a/m) hepatocellular carcinoma (HCC). Avelumab is a human anti–PD-L1